Table 2 Patient baseline characteristics by LPA16:0 subgroups
LPA16:0 | Low N = 45 | Medium N = 46 | High N = 45 | p value |
|---|---|---|---|---|
LPA16:0 tertile concentration (µM) | ||||
 Male |  < 0.12 | 0.12 to < 0.20 |  ≥ 0.20 |  |
 Female |  < 0.18 | 0.18 to < 0.30 |  ≥ 0.30 |  |
 Age (years) | 61.3 (7.6) | 67 (6.6)* | 65.3 (6.6)* | 0.00052 |
 Body mass index | 27.6 (5.3) | 25.3 (4.7) | 28.5 (5)+ | 0.0069 |
 Former smokers, % | 24 (53) | 29 (63) | 23 (51) | 0.47 |
Post-bronchodilator FEV1 | ||||
 Absolute (L) | 1.3 (0.5) | 1.3 (0.5) | 1.3 (0.4) | 0.56 |
 % predicted | 46.1 (17.2) | 46.4 (15.8) | 47.5 (12.6) | 0.90 |
 Post-bronchodilator FEV1/FVC ratio | 0.5 (0.1) | 0.5 (0.1) | 0.5 (0.1) | 0.83 |
 SGRQ-C score | 58.8 (17) | 55.7 (16.1) | 58.2 (20) | 0.68 |
GOLD, % | ||||
 Stage II | 20 (44.4) | 20 (43.5) | 22 (48.9) |  |
 Stage III | 13 (28.9) | 18 (39.1) | 18 (40.0) | 0.40 |
 Stage IV | 12 (26.7) | 8 (17.4) | 5 (11.1) |  |
Patients with chronic bronchitis, % | 39 (86.7) | 34 (73.9) | 34 (75.6) | 0.17 |
Patients with severe exacerbation in previous 12Â months, % | 13 (28.9) | 12 (26.1) | 12 (26.7) | 0.97 |
Median blood eosinophil count (cells/μL) | 185 (105) | 160 (97.5) | 200 (265) | 0.15 |
Median fibrinogen (g/L) | 3.5 (1.1) | 3.6 (1.5) | 3.5 (1) | 0.26 |